Transgene Update, page-4

Transgene update from the previously mentioned ESMO congress (Madrid):

* Presents additional positive clinical data from phase 2b part of time trial with TG4010 at European Society of Medical Oncology (ESMO) 2014 Congress in Madrid, Spain
* Announces statistically significant difference in progression-free survival continuing to be seen in non-squamous patient population
* Announces promising overall survival data, notably in subgroups of interest for the upcoming phase 3 trial

http://www.reuters.com/article/2014/09/29/transgene-brief-idUSFWN0RR00R20140929